MedPath

High Intensity Intervallic Training in Children With Bronchiolitis Obliterans

Not Applicable
Completed
Conditions
Bronchiolitis Obliterans
Interventions
Other: Exercise group
Registration Number
NCT05881538
Lead Sponsor
Universitat Internacional de Catalunya
Brief Summary

Post-Infectious Bronchiolitis Obliterans (PIBO) is an irreversible obstructive lung disease characterized by subepithelial inflammation and fibrotic narrowing of the bronchioles after lower respiratory tract infection. This disease is diagnosed mainly in children, more frequently before the age of 2 years. Due to symptoms such as dry cough and dyspnea sensation, most of these patients have low levels of physical activity compared to healthy individuals. Physical activity can positively influence oxygen consumption, muscle strength, and quality of life. High levels of oxygen consumption are associated with a lower risk of respiratory disease and hospitalization. High-intensity interval training (HIIT) may be an effective way to improve oxygen consumption, muscle strength, and quality of life in patients with chronic diseases. HIIT has been shown to produce less dyspnea sensation and to be more entertaining in children and adolescents with respiratory disease compared to continuous training. Thus, the investigators propose to perform telematically real-time guided training to reduce travel times and additional costs to patients.

Objective: To analyze the effects of a telematically supervised high-intensity intervallic training program on aerobic fitness, as well as functional/clinical outcomes in patients with PIBO.

Methods: Randomized controlled trial with two groups. Exercise group: 16-week HIIT training conducted telematically; Control group: will follow the routine physician's recommendations. Patients will be recruited at Vall D'Hebrón University Hospital (Barcelona), Niño Jesús University Hospital (Madrid), and Donostia Universitary Hospital (San Sebastián). Criteria for participation: (I) Diagnosis of PIBO; (II) Clinically stable at the time of the assessments; (III) Age between 6 to 20 years old.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
51
Inclusion Criteria
  • Diagnosis of Postinfectious bronchiolitis obliterans;
  • Clinical stability at the time of the assessments;
  • Age between 6 and 20 years old.
Read More
Exclusion Criteria
  • Symptoms of pulmonary exacerbation during the last four weeks;
  • Diagnosis of other cardiorespiratory diseases leading to symptoms of persistent respiratory dysfunction;
  • Difficulty in comprehension or musculoskeletal alterations that may influence the assessments;
  • Pregnancy;
  • Transplant list inclusion.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Exercise groupExercise group16 weeks of a "High Intensity Interval Training" exercise program conducted telematically with real time supervision twice a week. The exercise program consists of a circuit of exercises aiming to achieve a target heart rate for each fitness level.
Primary Outcome Measures
NameTimeMethod
Change in percent oxygen consumption at ventilatory thresholdChange from baseline to 16 weeks

Change in percent oxygen consumption at ventilatory threshold will be evaluated through cardiopulmonary exercise testing (CPET).

Change in ventilatory efficiencyChange from baseline to 16 weeks

Change in ventilatory efficiency will be evaluated by combining ventilation (VE) and carbon dioxide production (VCO2) measurements to report VE/VCO2 ratio, evaluated through cardiopulmonary exercise testing (CPET).

Change in peak oxygen consumptionChange from baseline to 16 weeks

Change in peak oxygen consumption (mL/kg/min) will be evaluated through cardiopulmonary exercise testing (CPET).

Change in time to ventilatory thresholdChange from baseline to 16 weeks

Change in time to ventilatory threshold (minutes) will be evaluated through cardiopulmonary exercise testing (CPET).

Secondary Outcome Measures
NameTimeMethod
Change in forced expiratory volume in the first secondChange from baseline to 16 weeks

Change in forced expiratory volume in the first second (liters) will be evaluated through spirometry.

Change in forced vital capacityChange from baseline to 16 weeks

Change in forced vital capacity (liters) will be evaluated through spirometry.

Change in forced expiratory flow between 25 and 75% of forced vital capacityChange from baseline to 16 weeks

Change in forced expiratory flow between 25 and 75% of forced vital capacity (liters/minute) will be evaluated through spirometry.

Change in free fat massChange from baseline to 16 weeks

Changes in free fat mass (percent) will be evaluated through bioimpedance.

Change in body mass indexChange from baseline to 16 weeks

Changes in body mass index will be evaluated by combining weight and height measurements to report BMI (kg/m\^2).

Change in dyspneaChange from baseline to 16 weeks

Changes in dyspnea will be evaluated through the Medical Research Council (mMRC) modified dyspnea scale. The overall result of the scale is a numerical value from 0 to 4, where the highest value corresponds to the worse dyspnea.

Change in muscle strengthChange from baseline to 16 weeks

Changes in muscle strength will be evaluated using a dynamometer.

Change in lower body strengthChange from baseline to 16 weeks

Changes in lower body strength will be evaluated using the 30 seconds Sit to Stand Test (30STS).

Change in lean massChange from baseline to 16 weeks

Changes in lean mass (percent) will be evaluated through bioimpedance.

Change in hip-waist ratioChange from baseline to 16 weeks

Changes in hip-waist ratio will be evaluated by combining hip circumference and waist circumference measurements using a non-stretchable tape measure.

Change in quality of lifeChange from baseline to 16 weeks

Changes in quality of life will be evaluated through the Saint George's Respiratory Questionnaire (SRQ). The overall result of the scale is a numerical value from 0 to 100, with the highest values corresponding to a worse quality of life.

Trial Locations

Locations (3)

Hospital Universitari Vall d'Hebron

🇪🇸

Barcelona, Catalunya, Spain

Hospital Universitario Donostia

🇪🇸

San Sebastián, País Vasco, Spain

Hospital Universitario Infantil Niño Jesús

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath